The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers

The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers

Joshua K Sabari,1 Fernando C Santini,1,2 Alison M Schram,2 Isabella Bergagnini,1 Ruqin Chen,1 Chebli Mrad,1 W Victoria Lai,1 Kathryn C Arbour,1 Alexander Drilon2,3 1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 2Developm...

Full description

Bibliographic Details
Main Authors: Sabari JK, Santini FC, Schram AM, Bergagnini I, Chen R, Mrad C, Lai WV, Arbour KC, Drilon A
Format: Article
Language:English
Published: Dove Medical Press 2017-04-01
Series:OncoTargets and Therapy
Subjects:
NSCLC
ALK
acquired resistance
tyrosine kinase inhibitor
brigatinib
crizotinib
ceritinib
alectinib
lorlatinib.
Online Access:https://www.dovepress.com/the-activity-safety-and-evolving-role-of-brigatinib-in-patients-with-a-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/the-activity-safety-and-evolving-role-of-brigatinib-in-patients-with-a-peer-reviewed-article-OTT

Similar Items